FY2026 Full year results
Filed with ASX · · 10 pages · English
Summary by 6ix AI
The report details FDA clearance and reimbursement for CT:VQ™, along with rapid adoption by leading U.S. academic medical centers and a distribution agreement with Philips. Financially, the company reported an increase in operating revenue and a substantial cash balance, positioning it well for future growth. The filing emphasizes the expansion of CT:VQ™ into international markets, including Europe and Australia, and partnerships with major pharmaceutical companies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from 4DMedical
- Appendix 4E - Preliminary Final Report
- Azra AI and 4DMedical Partner to Bring Enterprise-Wide Lung Health Intelligence to Health Systems
- Application for quotation of securities - 4DX
- Cleansing Notice
- Update - Proposed issue of securities - 4DX
Later from 4DMedical
- Notification of Date of 2026 AGM
- Ceasing to be a substantial holder
- Board transition and key personnel appointments
- Initial Director's Interest Notice - CJ
- FY26 Annual Report
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical